Do you want to know us better?
DOWNLOAD OUR PRESS KIT
OUR NEWS
The RADIOLA study identifies a complementary functional biomarker capable of distinguishing which patients with gBRCA, HER2-negative metastatic breast cancer may have up to a seven-fold higher likelihood of responding to olaparib
Led by SOLTI and conducted in scientific collaboration with the Vall d’Hebron Institute of Oncology (VHIO), the SOLTI-1910 RADIOLA study is the first prospective trial to
12 de December de 2025
The PremiÈRe study positions elacestrant as a promising treatment option for young women diagnosed with early breast cancer during premenopause
The phase 2 PremiÈRe clinical trial (SOLTI-2104) is the first to evaluate the oral drug elacestrant -alone or combined with ovarian function suppression- in premenopausal women
12 de December de 2025
A new chemotherapy-free combination reduces the risk of progression by 48% and improves tolerability in a molecularly selected group of patients with advanced breast cancer
In patients with ER+/HER2+ metastatic breast cancer of luminal subtype A or B, combined treatment with hormone therapy, trastuzumab and palbociclib significantly delays the time to
1 de June de 2024
